Idiopathic Orbital Inflammation Underlying Drug-Associated Thyroid Eye Disease

Authors

  • Hythem Abouodah The University of Kansas School of Medicine
  • Stephen L. Ambrose, M.D. University of Kansas Eye Center
  • Jordan E. Miller, M.D. University of Kansas Eye Center
  • Mary K. Mitchell University of Kansas School of Medicine
  • Jason A. Sokol, M.D. University of Kansas Eye Center Oculofacial Plastic and Orbital Surgery

DOI:

https://doi.org/10.17161/kjm.vol15.18210

Keywords:

Alemtuzumab, Thyroid, Graves', lymphoma, inflammatory

Downloads

Published

2022-10-24

Issue

Vol. 15 No. 3 (2022): Sept. - Dec.

Section

Case Reports

License

Copyright (c) 2022 Hythem Abouodah, Stephen L. Ambrose, M.D., Jordan E. Miller, M.D., Mary K. Mitchell, Jason A. Sokol, M.D.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

All articles in the Kansas Journal of Medicine are licensed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND 4.0). 

 

How to Cite

Abouodah, H., Ambrose, S. L., Miller, J. E., Mitchell, M. K., & Sokol, J. A. (2022). Idiopathic Orbital Inflammation Underlying Drug-Associated Thyroid Eye Disease. Kansas Journal of Medicine, 15(3), 380-381. https://doi.org/10.17161/kjm.vol15.18210